



Sarepta Therapeutics to Announce First Quarter 2025 Financial Results

4/22/25

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 22, 2025-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2025 financial results after the Nasdaq Global Market closes on Tuesday, May 6, 2025. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2025 financial results.

The event will be webcast live under the investor relations section of Sarepta's website at <https://investorrelations.sarepta.com/events-presentations> and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using [this online form](#). After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.

About Sarepta Therapeutics

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and limb-girdle muscular dystrophies (LGMDs) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit www.sarepta.com or follow us on [LinkedIn](#), [X](#), [Instagram](#) and [Facebook](#).

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

View source version on businesswire.com: <https://www.businesswire.com/news/home/2025042222092/en/>

Investor Contact:

Ian Estepan, 617-274-4052
iestepan@sarepta.com

Media Contact:

Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com

Source: Sarepta Therapeutics, Inc.